She works in academia as an internationally recognized neuropharmacology and neuroimmunology researcher. She published more than 500 scientific reports in the field of neuropsychopharmacology and signal transduction. She is leading a laboratory interested in understanding the fundamental neurobiological mechanisms of neuropsychiatric disorders to contribute at development of new pharmacological treatments. Uses genetic, neuroendocrine and neurochemical methods. She recognized the role of the immune system in modulating neuropsychiatric diseases and we are developing in vitro cellular models and in vivo animal models to study the neuro-immune interactions under normal and disease states. She has successfully combined research, teaching, administration and clinical care and continue to work on advancing and understanding the cause of serious mental illness and drug development. She hold patents for using modified peptides in the treatment of septic shock. She has a skills and expertise in receptor pharmacology, immunohistochemistry, in vivo and in vitro cell culture, biochemistry, animal models, cell and molecular biology. She has 19 years of research experience with development and use of in vitro models to test compounds, such as receptor binding, receptor activation, signal transduction, receptor-receptor interactions, and induction of changes in cell cycle, proliferation and apoptosis. Furthermore she validated appropriate assays and models of diseases, screen compounds, and study mechanisms of action.